Merkel-cell carcinoma

Last updated
Merkel cell carcinoma
Merkel cell carcinoma - very high mag.jpg
Micrograph of a Merkel cell carcinoma. H&E stain.
Specialty Oncology

Merkel-cell carcinoma (MCC) is a rare and aggressive skin cancer occurring in about three people per million members of the population. [1] It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, and trabecular carcinoma of the skin. [2] Factors involved in the development of MCC include the Merkel cell polyomavirus (MCPyV or MCV), a weakened immune system, and exposure to ultraviolet radiation. [3] Merkel-cell carcinoma usually arises on the head, neck, and extremities, as well as in the perianal region and on the eyelid. [4] It is more common in people over sixty years old, Caucasian people, and males. [5] MCC is less common in children. [1] [4]

Contents

Signs and symptoms

Small spot on the left arm is Merkel-cell cancer. Merkel cell carcinoma arm.jpg
Small spot on the left arm is Merkel-cell cancer.
Merkel-cell carcinoma. Gross pathology specimen. Merkel Cell Carcinoma buttock 45-year-old woman.jpg
Merkel-cell carcinoma. Gross pathology specimen.

Merkel-cell carcinoma (MCC) usually presents as a firm nodule (up to 2 cm diameter) or mass (>2 cm diameter). These flesh-colored, red, or blue tumors typically vary in size from 0.5 cm (less than one-quarter of an inch) to more than 5 cm (2 inches) in diameter and may enlarge rapidly. Tumors can present as painless, tender or itchy, and other MCC manifestations as papules or plaques have also been reported. [6] Although MCC may arise almost anywhere on the body, it is most commonly found in sun-exposed areas such as the head, neck or extremities. [7] Five key attributes of MCC were summarized in 2008 in the acronym AEIOU (Asymptomatic/lack of tenderness, Expanding rapidly, Immune suppression, Older than 50 years, and Ultraviolet-exposed site on a person with fair skin). [8] Ninety percent of MCC's have three or more of those features. [9] MCC is sometimes mistaken for other histological types of cancer, including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, lymphoma, and small cell carcinoma, or as a benign cyst. [10] Merkel-cell carcinomas have been described in children, however pediatric cases are very rare. [11]

Merkel-cell cancers tend to invade locally, infiltrating the underlying subcutaneous fat, fascia, and muscle, and typically metastasize early in their natural history, most often to the regional lymph nodes. MCCs also spread aggressively through the blood vessels to many organs, particularly to liver, lung, brain, and bone. [12]

Pathophysiology

Merkel-cell carcinoma (arrow) infiltrating skin tissue, stained brown for Merkel cell polyomavirus large T protein Merkelcellcarcinoma Tag.jpg
Merkel-cell carcinoma (arrow) infiltrating skin tissue, stained brown for Merkel cell polyomavirus large T protein

Cell of origin

Although MCC was initially named for the Merkel cell due to histologic and physiologic similarities between MCC and Merkel cells, the cellular progenitor of MCC has been a heavily debated question. Merkel cells are highly specialized cells that act as pressure receptors in the epidermis. The origin of Merkel cells themselves is debated and proposed to be derived from neural crest cells or epidermal progenitors. [14] MCC is similar to Merkel cells in its histological appearance (see below: Diagnosis) and shares many immunohistochemical markers with Merkel cells, including epidermal marker cytokeratin 20 and neuroendocrine markers synaptophysin and chromogranin A. Furthermore, the ion channel Piezo2 and transcription factor Atoh1, both specific to Merkel cells, are also expressed by MCC. [3] However, Merkel cells are post-mitotic cells with a low probability of cancerous transformation. [14] Additionally, they have not been shown to support Merkel-cell polyoma virus infection, which is believed to drive oncogenesis in approximately 80% of MCC. [15]

Instead, it has been proposed the MCC may originate from a Merkel cell precursor, at which point it gains features similar to those of Merkel cells. One such precursor is the human fibroblast. Evidence for a fibroblast precursor includes its location in the dermis, which is thought to be the primary site of origin for MCC. Additionally, in vitro experiments have demonstrated that fibroblasts not only support Merkel cell polyomavirus (MCV) infection but can be induced into having a MCC phenotype by the expression of viral proteins. [15] [16]

However, others have argued that MCC likely derives from an epithelial precursor cell due to its frequent presence in mixed tumors including epithelial neoplasms such as squamous cell carcinoma. While epithelial cells are not typically found in the dermis, hair follicles include epithelial cells that have been shown to have oncogenic potential, and have therefore been proposed as a possible site for a MCC precursor. [3] [17]

Finally, the presence of B-cell surface markers on MCC in addition to the high correlation between MCC and B-cell lymphomatous cancers have also led to suggestions that MCC may share a progenitor with B-cells. [3] [18] Because of the differences in physiology and prognosis between MCV+ and MCV- MCC (see below), however, some have suggested that these two subtypes of MCC may actually derive from different progenitor cells. [19]

Several factors are involved in the pathophysiology of MCC, including MCV, ultraviolet radiation (UV) exposure, and weakened immune function. [20]

Merkel cell polyomavirus

The MCV is a small double-stranded DNA virus that is believed to contribute to the development of the majority of MCC. [21] About 80% of MCC tumors are infected with MCV, with the virus integrated into the host genome in a monoclonal pattern. [21] However, the majority of people with MCV infection do not develop MCC: MCV is a ubiquitous virus and infection commonly occurs during childhood but remains asymptomatic throughout an individual's lifetime. [16]

MCC was first believed to be associated with MCV when it was observed to occur at a much higher rate in HIV patients during the 1980s. [22] Since then, studies have demonstrated integration of the MCV genome into the genome of MCC tumor cells. Central to the understanding of the pathogenicity of MCV are two viral proteins expressed in infected cells known as the large tumor antigen (LT) and small tumor antigen (sT). [23] Normally, patients infected with MCV show low levels of antibodies to the LT protein, perhaps due to a nuclear localization domain in its C-terminal that limits its cellular dispersion. However, integration of the viral genome into the host genome can result in truncation of the LT protein proximal to this domain. This serves two oncogenic purposes: first, it prevents successful viral replication that would culminate in lysis of the infected cell. Second, it redistributes the LT protein to the cytoplasm, where it can interact with cytoplasmic signaling. [24] The N-terminal LXCXE motif of the LT protein has been shown to interact with known oncogene Rb and is conserved in other cancer-causing viruses. [24] Studies suggest that LT may also preserve cell proliferation signals such as c-Myc and cyclin E and cause DNA injury to the p53 tumor suppressor. [15] [16]

Meanwhile, sT has been shown to induce cell proliferation through hyper-phosphorylation of the translation initiator 4EBP1 as well as inhibition of a ubiquitin ligase complex responsible for degradation of cellular proliferation signals. sT also contains a region known as the LT stabilization domain (LSD), which potentiates the LT protein's oncogenic function. Unlike LT, MCC samples have been identified that express sT alone, and sT expression in fibroblasts has been shown to cause MCC phenotype development. [15] [16]

UV light

About 20% of MCC tumors are MCV negative. [7] In contrast to MCV-induced MCC, these tumors tend to have much higher mutational burdens with mutational signatures characteristic of UV damage. [15] Genes frequently mutated in MCV-negative MCC include p53 and Rb, among others. [23] The link between MCC and UV exposure has been demonstrated through various epidemiological studies indicating a higher incidence of MCC in fair-skinned people in areas of high UV exposure, as well as among those receiving UV phototherapy. [6] The typical distribution of MCC in sun-exposed regions and its co-occurrence with other skin cancers also indicate that UV exposure is a contributing factor to MCC development. It is unclear whether this is through direct mutational impact, immune down-regulation, or some combination of the two. [6] [10]

Immunosuppression

The incidence of MCC is increased in conditions with defective immune functions such as malignancy, HIV infection, and organ transplant patients, etc. [6] Conversely, patients with brisk immune response have been shown to have improved prognoses. [25] This is suspected to be due to the inability of the body to defend itself from infection by or reactivation of MVC. [26] The body of data indicating the importance of immune function in MCC pathogenesis has been exploited for the development of immunotherapies discussed below.

Diagnosis

Photomicrographs of a typical Merkel-cell carcinoma at a 4x, b 40x, and c-d 100x objectives. Hematoxylin and eosin staining demonstrates small, undifferentiated cells with high N/C ratio and scanty cytoplasm. Typical immunopanel demonstrates positive staining with e cytokeratin AE1/AE3 (100x oil immersion), f CK 20 (100x oil immersion), and neuroendocrine markers such as g chromogranin (100x oil immersion). Micrographs of a typical merkel cell carcinoma.jpg
Photomicrographs of a typical Merkel-cell carcinoma at a 4x, b 40x, and c–d 100x objectives. Hematoxylin and eosin staining demonstrates small, undifferentiated cells with high N/C ratio and scanty cytoplasm. Typical immunopanel demonstrates positive staining with e cytokeratin AE1/AE3 (100x oil immersion), f CK 20 (100x oil immersion), and neuroendocrine markers such as g chromogranin (100x oil immersion).

Diagnosis of MCC begins with a clinical examination of the skin and lymph nodes to determine suspicious areas for further investigation. [28] Definitive diagnosis requires examination of biopsy tissue to identify its histopathologic features. [6] [28] An ideal biopsy specimen is either a punch biopsy or a full-thickness incisional biopsy of the skin including full-thickness dermis and subcutaneous fat. On light microscopy, MCC shows basaloid tumor nests with neuroendocrine features ("salt and pepper" chromatin, scarce cytoplasm, and brisk mitotic activity). [6] [28] In addition to standard examination under light microscopy, immunohistochemistry (IHC) is also generally required to differentiate MCC from other morphologically similar tumors such as skin metastases of small cell lung cancer, the small cell variant of melanoma, various cutaneous leukemic/lymphoid neoplasms, and Ewing's sarcoma. Neuroendocrine molecular markers such as synaptophysin or chromogranin A are characteristic of MCC and other neuroendocrine tumors, while other markers such as PAX5 or cytokeratin 20 can distinguish MCC from these tumors. [3] [7] Longitudinal imaging may also help in ruling out a diagnosis of metastatic small cell lung cancer. Once an MCC diagnosis is made, a sentinel lymph node biopsy as well as imaging are recommended as a part of the staging process, which determines prognosis and subsequent treatment options. [6] [28] Imaging may include positron emission tomography or CT scan. [29]

Prevention

Sunlight exposure is thought to be one of the causes of Merkel-cell carcinoma (MCC). The World Health Organization, American Academy of Dermatology, and Skin Cancer Foundation recommend the following measures to prevent excessive UV exposure and skin cancer: [30] [31] [32]

Treatment

Merkel-cell carcinoma is typically treated with surgery and radiation; immunotherapy is used in advanced disease. If an affected person is being treated with immunosuppressive drugs, they are reduced as much as possible. [29]

Surgery

Surgical resection is typically performed prior to other treatments, if possible. The type of surgery used may be a simple wide excision or a more specialized technique like Mohs surgery, depending on the individual. Part of the staging process – sentinel lymph node biopsy – is often performed at the same time. [29]

Radiation

Radiation therapy is the primary management of Merkel-cell carcinoma (MCC). The largest studies to date, from Australia, demonstrated that radiotherapy alone achieves equal outcomes with upfront or neoadjuvant surgery followed by radiation therapy. [33] [34] The role of surgery is largely historical and relegated to biopsy. There have been no head-to-head trials comparing the two treatment strategies, and in the absence of this, surgeons tend to most commonly perform excisional biopsy prior to referring for radiation therapy to eradicate MCC. MCC is exquisitely radiosensitive. [35] The conclusion amongst published studies in the Radiation Oncology community is that MCC should be managed ideally with radiation therapy alone. [34]

Chemotherapy

Because of its significant adverse effects, traditional chemotherapy has been saved for late-stage highly metastasized cases of MCC. While some chemotherapeutic regiments have been shown to have transient effects, studies have not found any significant long-term effect on recurrence rate or life expectancy. [15] As of 2015, there were no FDA-approved standard chemotherapy regimens for MCC treatment. [25] The most recent American guidelines do not recommend adjuvant chemotherapy, citing a lack of evidence to suggest improved outcomes. Instead, consideration of the need for chemotherapy on a case-by-case basis is recommended. [36]

Drug therapy

Immunotherapies, namely inhibitors of the PD1-PDL1 checkpoint signaling pathway, are novel anticancer agents that have shown benefit in advanced-stage MCC or chemotherapy-resistant MCC. [37] The PD-1 pathway is responsible for regulating the balance between T-cell activation and over-activation leading to T-cell exhaustion or autoimmunity. [38] However, over-expression of PD-1 ligands (PDL1) have been observed in tumors as a method of evading immune attack. [39] PD-1 inhibition therefore enhances the body's immune response, enabling it to target cancer cells for destruction. [40] Due to their side effects, however, National Comprehensive Cancer Network guidelines recommend PD-1 inhibitors for people with disseminated rather than early-stage MCC. [9]

PD1/PDL1 pathway inhibitors approved or in clinical trials for use in MCC treatment include:

Studies to date have shown a clinical response rate between 50 and 65% for MCC treated with PD-1 pathway inhibitors. Suggestions for further immunotherapy research areas have included therapeutic vaccines or epigenetic modification of HLA-receptors. [23] [24] [25] [37]

Prognosis

According to the American Joint Committee on Cancer (AJCC), the natural course of MCC is "variable and depends heavily on the stage at diagnosis". [45] Staging of MCC is classified according to the TNM staging system, a notation system that describes the stage of cancer according to the size of the primary tumor (T), the degree of spread to regional lymph nodes (N), and the presence of distant metastasis (M). [45] A combination of T, N, and M stages dictate the final clinical stage group (0, I, IIA, IIB, IIIA, IIIB, IV). [46] Advanced stage (i.e. increased size of the tumor, spreading of the tumor into surrounding and/or distant tissue, and involvement of lymph nodes) is associated with lower survival rates. [7]

The National Cancer Data Base has survival rates collected from nearly 3000 MCC patients from year 1996–2000 with 5-year survival rates listed as follows: [47] Stage IA: 80%. Stage IB: 60%. Stage IIA: 60%. Stage IIB: 50%. Stage IIC: 50%. Stage IIIA: 45%. Stage IIIB: 25%. Stage IV: 20%. Five-year survival may be 51% among people with localized disease, 35% for those with nodal disease, and 14% with metastases to a distant site. [9]

Several other features may also affect prognosis, independent of tumor stage. They include MCV viral status, histological features, and immune status. In viral status, MCV large tumor antigen (LT antigen) and retinoblastoma protein (RB protein) expression correlates with more favorable prognosis, while p63 expression correlates with a poorer prognosis. [48] [49] Histological features such as intratumoral CD8+ T lymphocyte infiltration may be associated with a favorable prognosis, while lymphovascular infiltrative pattern may be associated with a poorer prognosis. [50] [51] Immunosuppressed status, especially T cell immunosuppression (e.g., organ transplant, HIV infection, certain malignancy) predicts poorer prognosis and higher mortality. [52] Immunosuppression also raises the risk of recurrence. [29]

The antibody titer in the blood to the Merkel cell polyomavirus oncoprotein can be used as a treatment response biomarker in people that have detectable antibodies at the time of diagnosis. [53] [54]

Epidemiology

Merkel-cell carcinoma occurs most often in Caucasians between 60 and 80 years of age. Its incidence is about twice as high in males as in females. [55] It is a rare type of skin cancer, with a 2013 incidence of only 0.7 per 100,000 persons in the U.S. [56] As of 2005, roughly 2,500 new cases of MCC are diagnosed each year in the United States, [56] as compared to around 60,000 new cases of malignant melanoma and over 1 million new cases of nonmelanoma skin cancer. [57] Similar to melanoma, the incidence of MCC in the US is increasing rapidly. [10] Worldwide, MCC is most commonly found in regions with increased sun exposure. Australia is the country with the highest incidence of MCC [55] but has a lower incidence of MCV-positive MCC than observed in other countries. [58]

Since 2006, it has been known that other primary cancers increase the risk of MCC significantly, especially in those with the prior multiple myeloma, chronic lymphocytic leukemia, and malignant melanoma. [59] Immunosuppression including HIV infection or immunosuppressant therapy following organ transplant or for autoimmune disease can also increase the odds of developing MCC. [20]

History

Friedrich Sigmund Merkel (1845–1919) was a German anatomist and histopathologist who first described the Tastzellen (touch cells) in the skin in 1875. [60] In 1878 the term Merkel cell was coined by the anatomist Robert Bonnet (1851–1921).

Merkel-cell carcinoma was first described in 1972 by Cyril Toker. [61] He reported five cases of 'trabecular carcinoma of the skin'.

Notable patients

Related Research Articles

<span class="mw-page-title-main">Skin cancer</span> Medical condition involving uncontrolled growth of skin cells

Skin cancers are cancers that arise from the skin. They are due to the development of abnormal cells that have the ability to invade or spread to other parts of the body. Skin cancer is the most commonly diagnosed form of cancer in humans. There are three main types of skin cancers: basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. The first two, along with a number of less common skin cancers, are known as nonmelanoma skin cancer (NMSC). Basal-cell cancer grows slowly and can damage the tissue around it but is unlikely to spread to distant areas or result in death. It often appears as a painless raised area of skin that may be shiny with small blood vessels running over it or may present as a raised area with an ulcer. Squamous-cell skin cancer is more likely to spread. It usually presents as a hard lump with a scaly top but may also form an ulcer. Melanomas are the most aggressive. Signs include a mole that has changed in size, shape, color, has irregular edges, has more than one color, is itchy or bleeds.

<span class="mw-page-title-main">Cutaneous squamous-cell carcinoma</span> Medical condition

Cutaneous squamous-cell carcinoma (cSCC), or squamous-cell carcinoma of the skin, also known as squamous-cell skin cancer, is, with basal-cell carcinoma and melanoma, one of the three principal types of skin cancer. cSCC typically presents as a hard lump with a scaly top layer, but it may instead form an ulcer. Onset often occurs over a period of months. Cutaneous squamous-cell carcinoma is more likely to spread to distant areas than basal cell cancer. When confined to the outermost layer of the skin, a pre-invasive, or in situ, form of cSCC is known as Bowen's disease.

<span class="mw-page-title-main">Basal-cell carcinoma</span> Most common type of skin cancer

Basal-cell carcinoma (BCC), also known as basal-cell cancer, basalioma or rodent ulcer, is the most common type of skin cancer. It often appears as a painless raised area of skin, which may be shiny with small blood vessels running over it. It may also present as a raised area with ulceration. Basal-cell cancer grows slowly and can damage the tissue around it, but it is unlikely to spread to distant areas or result in death.

<span class="mw-page-title-main">Melanoma</span> Cancer originating in melanocytes

Melanoma, also redundantly known as malignant melanoma, is a type of cancer that develops from the pigment-producing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men, they most commonly occur on the back. About 25% of melanomas develop from moles. Changes in a mole that can indicate melanoma include an increase in size, irregular edges, change in color, itchiness, or skin breakdown.

<span class="mw-page-title-main">Head and neck cancer</span> Cancer arises in the head or neck region

Head and neck cancer develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary glands, nose, sinuses, or skin of the face. The most common types of head and neck cancer occur in the lips, mouth, and larynx. Symptoms predominantly include a sore that does not heal or a change in the voice. In those with advanced disease, there may be unusual bleeding, facial pain, numbness or swelling, and visible lumps on the outside of the neck or oral cavity. Given the location of these cancers, it is possible for an afflicted individual to experience difficulty in breathing.

<i>Polyomaviridae</i> Family of viruses

Polyomaviridae is a family of viruses whose natural hosts are primarily mammals and birds. As of 2020, there are six recognized genera and 117 species, five of which are unassigned to a genus. 14 species are known to infect humans, while others, such as Simian Virus 40, have been identified in humans to a lesser extent. Most of these viruses are very common and typically asymptomatic in most human populations studied. BK virus is associated with nephropathy in renal transplant and non-renal solid organ transplant patients, JC virus with progressive multifocal leukoencephalopathy, and Merkel cell virus with Merkel cell cancer.

<span class="mw-page-title-main">Actinic keratosis</span> Skin disorder

Actinic keratosis (AK), sometimes called solar keratosis or senile keratosis, is a pre-cancerous area of thick, scaly, or crusty skin. Actinic keratosis is a disorder of epidermal keratinocytes that is induced by ultraviolet (UV) light exposure. These growths are more common in fair-skinned people and those who are frequently in the sun. They are believed to form when skin gets damaged by UV radiation from the sun or indoor tanning beds, usually over the course of decades. Given their pre-cancerous nature, if left untreated, they may turn into a type of skin cancer called squamous cell carcinoma. Untreated lesions have up to a 20% risk of progression to squamous cell carcinoma, so treatment by a dermatologist is recommended.

<span class="mw-page-title-main">Mycosis fungoides</span> Most common form of cutaneous T-cell lymphoma

Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form of cutaneous T-cell lymphoma. It generally affects the skin, but may progress internally over time. Symptoms include rash, tumors, skin lesions, and itchy skin.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

<span class="mw-page-title-main">Vulvar cancer</span> Cancer involving the vulva

Vulvar cancer is a cancer of the vulva, the outer portion of the female genitals. It most commonly affects the labia majora. Less often, the labia minora, clitoris, or Bartholin's glands are affected. Symptoms include a lump, itchiness, changes in the skin, or bleeding from the vulva.

<span class="mw-page-title-main">Transitional cell carcinoma</span> Medical condition

Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. Symptoms of urothelial carcinoma in the bladder include hematuria. Diagnosis includes urine analysis and imaging of the urinary tract (cystoscopy). Transitional cell carcinomas arise from the transitional epithelium, a tissue lining the inner surface of these hollow organs. When the term "urothelial" is used, it specifically refers to a carcinoma of the urothelium, meaning a transitional cell carcinomas of the urinary system.

<span class="mw-page-title-main">Thymic carcinoma</span> Medical condition

Thymic carcinoma, or type C thymoma, is a malignancy of the thymus. It is a rare cancer that is often diagnosed at advanced stages. Recurrence following treatment is common, and thymic carcinoma is associated with a poor prognosis.

Merkel cell polyomavirus was first described in January 2008 in Pittsburgh, Pennsylvania. It was the first example of a human viral pathogen discovered using unbiased metagenomic next-generation sequencing with a technique called digital transcriptome subtraction. MCV is one of seven currently known human oncoviruses. It is suspected to cause the majority of cases of Merkel cell carcinoma, a rare but aggressive form of skin cancer. Approximately 80% of Merkel cell carcinoma (MCC) tumors have been found to be infected with MCV. MCV appears to be a common—if not universal—infection of older children and adults. It is found in respiratory secretions, suggesting that it might be transmitted via a respiratory route. However, it has also been found elsewhere, such as in shedded healthy skin and gastrointestinal tract tissues, thus its precise mode of transmission remains unknown. In addition, recent studies suggest that this virus may latently infect the human sera and peripheral blood mononuclear cells.

<span class="mw-page-title-main">Kaposi's sarcoma</span> Cancer of the skin, integumentary lymph nodes, or other organs

Kaposi's sarcoma (KS) is a type of cancer that can form masses in the skin, in lymph nodes, in the mouth, or in other organs. The skin lesions are usually painless, purple and may be flat or raised. Lesions can occur singly, multiply in a limited area, or may be widespread. Depending on the sub-type of disease and level of immune suppression, KS may worsen either gradually or quickly. Except for Classical KS where there is generally no immune suppression, KS is caused by a combination of immune suppression and infection by Human herpesvirus 8.

<span class="mw-page-title-main">Sebaceous carcinoma</span> Medical condition

Sebaceous carcinoma, also known as sebaceous gland carcinoma (SGc), sebaceous cell carcinoma, and meibomian gland carcinoma is an uncommon malignant cutaneous tumor. Most are typically about 1.4 cm at presentation. SGc originates from sebaceous glands in the skin and, therefore, may originate anywhere in the body where these glands are found. SGc can be divided into 2 types: periocular and extraocular. The periocular region is rich in sebaceous glands making it a common site of origin. The cause of these lesions in the vast majority of cases is unknown. Occasional cases may be associated with Muir-Torre syndrome. SGc accounts for approximately 0.7% of all skin cancers, and the incidence of SGc is highest in Caucasian, Asian, and Indian populations. Due to the rarity of this tumor and variability in clinical and histological presentation, SGc is often misdiagnosed as an inflammatory condition or a more common neoplasm. SGc is commonly treated with wide local excision or Mohs micrographic surgery, and the relative survival rates at 5 and 10 years are 92.72 and 86.98%, respectively.

<span class="mw-page-title-main">Wolfram Samlowski</span> Oncologist

Wolfram Samlowski is an American medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN) and a member of the Research Developmental Therapeutics and Genitourinary Committees for US Oncology. His research interests include translational research and development of novel cancer immunotherapy agents, translational drug development as well as gene therapy. His clinical interests are in developing more effective treatments for advanced stages of melanoma and non-melanoma skin cancers, and renal cancer.

Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.

<span class="mw-page-title-main">PD-1 and PD-L1 inhibitors</span> Class of anticancer drugs

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.

<span class="mw-page-title-main">Squamous-cell carcinoma</span> Carcinoma that derives from squamous epithelial cells

Squamous-cell carcinoma (SCC), also known as epidermoid carcinoma, comprises a number of different types of cancer that begin in squamous cells. These cells form on the surface of the skin, on the lining of hollow organs in the body, and on the lining of the respiratory and digestive tracts.

References

  1. 1 2 "Merkel-cell carcinima". Dynamed. Retrieved 2019-11-11.
  2. ↑ Dermatology. Bolognia, Jean., Jorizzo, Joseph L., Rapini, Ronald P. (2nd ed.). St. Louis, MO: Mosby/Elsevier. 2008. ISBN   978-1-4160-2999-1. OCLC   212399895.{{cite book}}: CS1 maint: others (link)[ page needed ]
  3. 1 2 3 4 5 Kervarrec, Thibault; Samimi, Mahtab; Guyétant, Serge; Sarma, Bhavishya; Chéret, Jérémy; Blanchard, Emmanuelle; Berthon, Patricia; Schrama, David; Houben, Roland; Touzé, Antoine (10 June 2019). "Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review". Frontiers in Oncology. 9: 451. doi: 10.3389/fonc.2019.00451 . PMC   6579919 . PMID   31245285.
  4. 1 2 Patterson, James W. (James Willis), 1946- (2014-12-07). Weedon's skin pathology. Hosler, Gregory A. (Fourth ed.). [Edinburgh?]. ISBN   978-0-7020-6200-1. OCLC   900724639.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  5. ↑ Pulitzer, Melissa (June 2017). "Merkel Cell Carcinoma". Surgical Pathology Clinics. 10 (2): 399–408. doi:10.1016/j.path.2017.01.013. PMC   5443625 . PMID   28477888.
  6. 1 2 3 4 5 6 7 Coggshall, Kathleen; Tello, Tiffany L.; North, Jeffrey P.; Yu, Siegrid S. (March 2018). "Merkel cell carcinoma: An update and review". Journal of the American Academy of Dermatology. 78 (3): 433–442. doi: 10.1016/j.jaad.2017.12.001 . PMID   29229574.
  7. 1 2 3 4 Emge, Drew A.; Cardones, Adela R. (October 2019). "Updates on Merkel Cell Carcinoma". Dermatologic Clinics. 37 (4): 489–503. doi:10.1016/j.det.2019.06.002. PMID   31466589. S2CID   201673379.
  8. ↑ Heath, Michelle; Jaimes, Natalia; Lemos, Bianca; Mostaghimi, Arash; Wang, Linda C.; Peñas, Pablo F.; Nghiem, Paul (March 2008). "Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features". Journal of the American Academy of Dermatology. 58 (3): 375–381. doi:10.1016/j.jaad.2007.11.020. PMC   2335370 . PMID   18280333.
  9. 1 2 3 Voelker, Rebecca (3 July 2018). "Why Merkel Cell Cancer Is Garnering More Attention". JAMA. 320 (1): 18–20. doi:10.1001/jama.2018.7042. PMID   29898204. S2CID   49191126.
  10. 1 2 3 Schrama, David; Ugurel, Selma; Becker, Jürgen C. (March 2012). "Merkel cell carcinoma". Current Opinion in Oncology. 24 (2): 141–149. doi:10.1097/CCO.0b013e32834fc9fe. PMID   22234254. S2CID   31864646.
  11. ↑ Paulson, Kelly G.; Nghiem, Paul (June 2019). "One in a hundred million: Merkel cell carcinoma in pediatric and young adult patients is rare but more likely to present at advanced stages based on US registry data". Journal of the American Academy of Dermatology. 80 (6): 1758–1760. doi:10.1016/j.jaad.2018.08.021. PMC   6487227 . PMID   30165170.
  12. ↑ "Merkel Cell Carcinoma Treatment". National Cancer Institute. 2006-02-21. Retrieved 2018-03-04.
  13. ↑ Shuda, Masahiro; Arora, Reety; Kwun, Hyun Jin; Feng, Huichen; Sarid, Ronit; Fernández-Figueras, María-Teresa; Tolstov, Yanis; Gjoerup, Ole; Mansukhani, Mahesh M.; Swerdlow, Steven H.; Chaudhary, Preet M.; Kirkwood, John M.; Nalesnik, Michael A.; Kant, Jeffrey A.; Weiss, Lawrence M.; Moore, Patrick S.; Chang, Yuan (15 September 2009). "Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors". International Journal of Cancer. 125 (6): 1243–1249. doi:10.1002/ijc.24510. PMC   6388400 . PMID   19499546.
  14. 1 2 Cook, Deborah L.; Frieling, Gretchen W. (April 2016). "Merkel cell carcinoma: a review and update on current concepts". Diagnostic Histopathology. 22 (4): 127–133. doi:10.1016/j.mpdhp.2016.04.002.
  15. 1 2 3 4 5 6 MacDonald, Margo; You, Jianxin (2017). "Merkel Cell Polyomavirus: A New DNA Virus Associated with Human Cancer". Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. Advances in Experimental Medicine and Biology. Vol. 1018. pp. 35–56. doi:10.1007/978-981-10-5765-6_4. ISBN   978-981-10-5764-9. PMID   29052131.
  16. 1 2 3 4 DeCaprio, James A. (11 September 2017). "Merkel cell polyomavirus and Merkel cell carcinoma". Philosophical Transactions of the Royal Society B: Biological Sciences. 372 (1732): 20160276. doi:10.1098/rstb.2016.0276. PMC   5597743 . PMID   28893943.
  17. ↑ Walsh, Noreen M.G. (July 2001). "Primary neuroendocrine (Merkel cell) carcinoma of the skin: Morphologic diversity and implications thereof". Human Pathology. 32 (7): 680–689. doi:10.1053/hupa.2001.25904. PMID   11486166.
  18. ↑ Tadmor, T.; Aviv, A.; Polliack, A. (February 2011). "Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties". Annals of Oncology. 22 (2): 250–256. doi: 10.1093/annonc/mdq308 . PMID   20587511.
  19. ↑ Sunshine, J. C.; Jahchan, N. S.; Sage, J.; Choi, J. (11 January 2018). "Are there multiple cells of origin of Merkel cell carcinoma?". Oncogene. 37 (11): 1409–1416. doi:10.1038/s41388-017-0073-3. PMC   5854515 . PMID   29321666.
  20. 1 2 Rotondo, John Charles; Bononi, Ilaria; Puozzo, Andrea; Govoni, Marcello; Foschi, Valentina; Lanza, Giovanni; Gafà, Roberta; Gaboriaud, Pauline; Touzé, Françoise Antoine; Selvatici, Rita; Martini, Fernanda; Tognon, Mauro (15 July 2017). "Merkel Cell Carcinomas Arising in Autoimmune Disease Affected Patients Treated with Biologic Drugs, Including Anti-TNF". Clinical Cancer Research. 23 (14): 3929–3934. doi: 10.1158/1078-0432.CCR-16-2899 . hdl: 11392/2378829 . PMID   28174236.
  21. 1 2 Amber, Kyle; McLeod, Michael P.; Nouri, Keyvan (February 2013). "The Merkel Cell Polyomavirus and Its Involvement in Merkel Cell Carcinoma". Dermatologic Surgery. 39 (2): 232–238. doi:10.1111/dsu.12079. PMID   23387356. S2CID   41973334.
  22. ↑ Engels, Eric A; Frisch, Morten; Goedert, James J; Biggar, Robert J; Miller, Robert W (February 2002). "Merkel cell carcinoma and HIV infection". The Lancet. 359 (9305): 497–498. doi:10.1016/S0140-6736(02)07668-7. PMID   11853800. S2CID   11934339.
  23. 1 2 3 4 Becker, Jürgen C.; Stang, Andreas; Hausen, Axel zur; Fischer, Nicole; DeCaprio, James A.; Tothill, Richard W.; Lyngaa, Rikke; Hansen, Ulla Kring; Ritter, Cathrin; Nghiem, Paul; Bichakjian, Christopher K.; Ugurel, Selma; Schrama, David (30 November 2017). "Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC". Cancer Immunology, Immunotherapy. 67 (3): 341–351. doi:10.1007/s00262-017-2099-3. PMC   6015651 . PMID   29188306.
  24. 1 2 3 Tabachnick-Cherny, Shira; Pulliam, Thomas; Church, Candice; Koelle, David M.; Nghiem, Paul (27 March 2020). "Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development". Molecular Carcinogenesis. 59 (7): 807–821. doi: 10.1002/mc.23190 . PMC   8238237 . PMID   32219902.
  25. 1 2 3 Harms, Paul W.; Harms, Kelly L.; Moore, Patrick S.; DeCaprio, James A.; Nghiem, Paul; Wong, Michael K. K.; Brownell, Isaac; International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working, Group. (4 October 2018). "The biology and treatment of Merkel cell carcinoma: current understanding and research priorities". Nature Reviews Clinical Oncology. 15 (12): 763–776. doi:10.1038/s41571-018-0103-2. PMC   6319370 . PMID   30287935.
  26. ↑ de Visser, Karin E.; Eichten, Alexandra; Coussens, Lisa M. (January 2006). "Paradoxical roles of the immune system during cancer development". Nature Reviews Cancer. 6 (1): 24–37. doi:10.1038/nrc1782. PMID   16397525. S2CID   29491641.
  27. ↑ Nguyen, Austin Huy; Tahseen, Ahmed I.; Vaudreuil, Adam M.; Caponetti, Gabriel C.; Huerter, Christopher J. (25 January 2017). "Clinical features and treatment of vulvar Merkel cell carcinoma: a systematic review". Gynecologic Oncology Research and Practice. 4 (1): 2. doi: 10.1186/s40661-017-0037-x . PMC   5264489 . PMID   28138393.
  28. 1 2 3 4 Amaral, Teresa; Leiter, Ulrike; Garbe, Claus (16 September 2017). "Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy". Reviews in Endocrine and Metabolic Disorders. 18 (4): 517–532. doi:10.1007/s11154-017-9433-0. PMID   28916903. S2CID   3937505.
  29. 1 2 3 4 "NCCN Guidelines Version 1.2023 Merkel Cell Carcinoma" (PDF). National Comprehensive Cancer Network. April 10, 2023.
  30. ↑ "Sun protection". World Health Organization. Retrieved 2018-03-28.
  31. ↑ "Prevention Guidelines – SkinCancer.org". www.skincancer.org. Retrieved 2018-03-28.
  32. ↑ "Prevent skin cancer | American Academy of Dermatology". www.aad.org. Retrieved 2018-03-28.
  33. ↑ Pape, Emeline; Rezvoy, Nicolas; Penel, Nicolas; Salleron, Julia; Martinot, Veronique; Guerreschi, Pierre; Dziwniel, Veronique; Darras, Sophie; Mirabel, Xavier; Mortier, Laurent (November 2011). "Radiotherapy alone for Merkel cell carcinoma: A comparative and retrospective study of 25 patients". Journal of the American Academy of Dermatology. 65 (5): 983–990. doi:10.1016/j.jaad.2010.07.043. PMID   21641081.
  34. 1 2 Veness, Michael; Foote, Matthew; Gebski, Val; Poulsen, Michael (November 2010). "The Role of Radiotherapy Alone in Patients With Merkel Cell Carcinoma: Reporting the Australian Experience of 43 Patients". International Journal of Radiation Oncology, Biology, Physics. 78 (3): 703–709. doi:10.1016/j.ijrobp.2009.08.011. PMID   19939581.
  35. ↑ Gortman, Aron (2019). "Definitive Radiotherapy for Locally Advanced Merkel Cell Carcinoma of the Head and Neck Region: A Case Report". Cureus. 11 (12): e6270. doi: 10.7759/cureus.6270 . PMC   6937466 . PMID   31903306.
  36. ↑ Bichakjian, Christopher K.; Olencki, Thomas; Aasi, Sumaira Z.; Alam, Murad; Andersen, James S.; Blitzblau, Rachel; Bowen, Glen M.; Contreras, Carlo M.; Daniels, Gregory A.; Decker, Roy; Farma, Jeffrey M.; Fisher, Kris; Gastman, Brian; Ghosh, Karthik; Grekin, Roy C.; Grossman, Kenneth; Ho, Alan L.; Lewis, Karl D.; Loss, Manisha; Lydiatt, Daniel D.; Messina, Jane; Nehal, Kishwer S.; Nghiem, Paul; Puzanov, Igor; Schmults, Chrysalyne D.; Shaha, Ashok R.; Thomas, Valencia; Xu, Yaohui G.; Zic, John A.; Hoffmann, Karin G.; Engh, Anita M. (11 June 2018). "Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology". Journal of the National Comprehensive Cancer Network. 16 (6): 742–774. doi: 10.6004/jnccn.2018.0055 . PMC   9440150 . PMID   29891526.
  37. 1 2 Becker, Jürgen C.; Stang, Andreas; DeCaprio, James A.; Cerroni, Lorenzo; Lebbé, Celeste; Veness, Michael; Nghiem, Paul (26 October 2017). "Merkel cell carcinoma". Nature Reviews Disease Primers. 3 (1): 17077. doi:10.1038/nrdp.2017.77. PMC   6054450 . PMID   29072302.
  38. ↑ Sharpe, Arlene H.; Pauken, Kristen E. (13 November 2017). "The diverse functions of the PD1 inhibitory pathway". Nature Reviews Immunology. 18 (3): 153–167. doi:10.1038/nri.2017.108. PMID   28990585. S2CID   3509381.
  39. ↑ LaFleur, Martin W.; Muroyama, Yuki; Drake, Charles G.; Sharpe, Arlene H. (8 January 2018). "Inhibitors of the PD-1 Pathway in Tumor Therapy". The Journal of Immunology. 200 (2): 375–383. doi:10.4049/jimmunol.1701044. PMC   5924692 . PMID   29311378.
  40. ↑ Topalian, Suzanne L.; Drake, Charles G.; Pardoll, Drew M. (April 2015). "Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy". Cancer Cell. 27 (4): 450–461. doi:10.1016/j.ccell.2015.03.001. PMC   4400238 . PMID   25858804.
  41. ↑ FDA approves first treatment for rare form of skin cancer FDA News Release, March 23, 2017
  42. ↑ Archived 2013-08-19 at the Wayback Machine FDA News Release, December 19, 2018
  43. 1 2 "Immunotherapy for Merkel Cell Carcinoma | Merkel Cell Carcinoma" . Retrieved 2020-05-14.
  44. ↑ Clinical trial number NCT01913691 for "Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma" at ClinicalTrials.gov
  45. 1 2 AJCC cancer staging manual. Amin, Mahul B.,, Edge, Stephen B.,, American Joint Committee on Cancer (Eighth ed.). Switzerland. 2018-03-30. ISBN   978-3-319-40617-6. OCLC   961218414.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)[ page needed ]
  46. ↑ "PDQ (Physician Data Query)". JNCI Journal of the National Cancer Institute. 105 (21): 1592–1593. 18 October 2013. doi: 10.1093/jnci/djt327 .
  47. ↑ "Survival Rates for Merkel Cell Carcinoma, by Stage". www.cancer.org. Retrieved 2018-03-03.
  48. ↑ Sihto, H.; Kukko, H.; Koljonen, V.; Sankila, R.; Bohling, T.; Joensuu, H. (3 June 2011). "Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinoma". Clinical Cancer Research. 17 (14): 4806–4813. doi: 10.1158/1078-0432.CCR-10-3363 . PMID   21642382.
  49. ↑ Stetsenko, Galina Y.; Malekirad, Jacqueline; Paulson, Kelly G.; Iyer, Jayasri G.; Thibodeau, Renee M.; Nagase, Kotaro; Schmidt, Miranda; Storer, Barry E.; Argenyi, Zsolt B.; Nghiem, Paul (1 December 2013). "p63 Expression in Merkel Cell Carcinoma Predicts Poorer Survival yet May Have Limited Clinical Utility". American Journal of Clinical Pathology. 140 (6): 838–844. doi:10.1309/AJCPE4PK6CTBNQJY. PMC   4074520 . PMID   24225752.
  50. ↑ Paulson, Kelly G.; Iyer, Jayasri G.; Tegeder, Andrew R.; Thibodeau, Renee; Schelter, Janell; Koba, Shinichi; Schrama, David; Simonson, William T.; Lemos, Bianca D.; Byrd, David R.; Koelle, David M.; Galloway, Denise A.; Leonard, J. Helen; Madeleine, Margaret M.; Argenyi, Zsolt B.; Disis, Mary L.; Becker, Juergen C.; Cleary, Michele A.; Nghiem, Paul (20 April 2011). "Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival". Journal of Clinical Oncology. 29 (12): 1539–1546. doi:10.1200/JCO.2010.30.6308. PMC   3082974 . PMID   21422430.
  51. ↑ Andea, Aleodor A.; Coit, Daniel G.; Amin, Bijal; Busam, Klaus J. (1 November 2008). "Merkel cell carcinoma". Cancer. 113 (9): 2549–2558. doi: 10.1002/cncr.23874 . PMID   18798233. S2CID   33020916.
  52. ↑ Asgari, Maryam M.; Sokil, Monica M.; Warton, E. Margaret; Iyer, Jayasri; Paulson, Kelly G.; Nghiem, Paul (1 July 2014). "Effect of Host, Tumor, Diagnostic, and Treatment Variables on Outcomes in a Large Cohort With Merkel Cell Carcinoma". JAMA Dermatology. 150 (7): 716–23. doi:10.1001/jamadermatol.2013.8116. PMC   4141075 . PMID   24807619.
  53. ↑ Paulson, Kelly G.; Bhatia, Shailender (11 June 2018). "Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide". Journal of the National Comprehensive Cancer Network. 16 (6): 782–790. doi: 10.6004/jnccn.2018.7049 . PMID   29891528.
  54. ↑ Paulson, Kelly G.; Lewis, Christopher W.; Redman, Mary W.; Simonson, William T.; Lisberg, Aaron; Ritter, Deborah; Morishima, Chihiro; Hutchinson, Kathleen; Mudgistratova, Lola; Blom, Astrid; Iyer, Jayasri; Moshiri, Ata S.; Tarabadkar, Erica S.; Carter, Joseph J.; Bhatia, Shailender; Kawasumi, Masaoki; Galloway, Denise A.; Wener, Mark H.; Nghiem, Paul (15 April 2017). "Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study". Cancer. 123 (8): 1464–1474. doi:10.1002/cncr.30475. PMC   5384867 . PMID   27925665.
  55. 1 2 Schadendorf, Dirk; Lebbé, Céleste; zur Hausen, Axel; Avril, Marie-Françoise; Hariharan, Subramanian; Bharmal, Murtuza; Becker, Jürgen C. (January 2017). "Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs". European Journal of Cancer. 71: 53–69. doi: 10.1016/j.ejca.2016.10.022 . PMID   27984768.
  56. 1 2 Paulson, Kelly G.; Park, Song Youn; Vandeven, Natalie A.; Lachance, Kristina; Thomas, Hannah; Chapuis, Aude G.; Harms, Kelly L.; Thompson, John A.; Bhatia, Shailender; Stang, Andreas; Nghiem, Paul (March 2018). "Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics". Journal of the American Academy of Dermatology. 78 (3): 457–463.e2. doi:10.1016/j.jaad.2017.10.028. PMC   5815902 . PMID   29102486.
  57. ↑ Hodgson, Nicole C. (1 January 2005). "Merkel cell carcinoma: Changing incidence trends". Journal of Surgical Oncology. 89 (1): 1–4. doi:10.1002/jso.20167. PMID   15611998. S2CID   27828135.
  58. ↑ Garneski, Kelly M.; Warcola, Ashley H.; Feng, Qinghua; Kiviat, Nancy; Leonard, J. Helen; Nghiem, Paul (2009). "Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors". The Journal of Investigative Dermatology. 129 (1): 246–248. doi:10.1038/jid.2008.229. PMC   2605200 . PMID   18650846.
  59. ↑ Howard, R. A.; Dores, GM; Curtis, RE; Anderson, WF; Travis, LB (1 August 2006). "Merkel Cell Carcinoma and Multiple Primary Cancers". Cancer Epidemiology, Biomarkers & Prevention. 15 (8): 1545–1549. doi: 10.1158/1055-9965.EPI-05-0895 . PMID   16896047.
  60. ↑ Merkel, F (1875). "Tastzellen und Tastkörperchen bei den Hausthieren und beim Menschen" [Probe cells and probe bodies in domestic animals and in humans]. Archiv für mikroskopische Anatomie (in German). 11 (1): 636–652. doi:10.1007/BF02933819. S2CID   83793552.
  61. ↑ Toker, Cyril (January 1972). "Trabecular carcinoma of the skin". Archives of Dermatology. 105 (1): 107–110. doi:10.1001/archderm.1972.01620040075020. PMID   5009611.
  62. ↑ Staff and Wire Reports (2004-12-12). "David Brudnoy, 64; Talk Radio Host Was Heard in 38 States". Los Angeles Times. Retrieved 2022-04-25.
  63. ↑ Obituaries, Telegraph (10 June 2018). "Maria Bueno, three-times women's singles champion at Wimbledon – obituary". The Telegraph.
  64. ↑ JimmyBuffett.com obituary (2023-09-01). "Jimmy Buffett 1946-2023". JimmyBuffett.com. Retrieved 2023-09-02.
  65. ↑ "Copelands Help Save Life of Family's Doctor". www.lsuhsc.edu. Retrieved 2022-04-25.
  66. ↑ Farooq, Sajid (28 October 2011). "Al Davis Death Certificate Reveals Cause of Death". KNTV . Retrieved 3 September 2023.
  67. ↑ Shapiro, T. Rees (2012-01-18). "Edward J. Derwinski, first secretary of the Department of Veterans Affairs, dies". Washington Post. ISSN   0190-8286 . Retrieved 2022-04-25.
  68. ↑ Martin, Douglas (2012-11-01). "John Fitch, Glamorous Racer With a Flair for Danger, Dies at 95". The New York Times. ISSN   0362-4331 . Retrieved 2022-04-25.
  69. ↑ Colker, David (6 February 2014). "Leonard Hirshan dies at 86; longtime agent for Clint Eastwood". Los Angeles Times. Retrieved 3 September 2023.
  70. ↑ Yardley, William (2014-04-09). "Gen. Carl E. Mundy Jr., Outspoken Marine Corps Leader, Dies at 78". The New York Times. ISSN   0362-4331 . Retrieved 2022-04-25.
  71. ↑ Keepnews, Peter (12 September 2007). "Joe Zawinul, 75, Jazz Fusion Pioneer, Dies". The New York Times.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.